Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Aspirin associated with reduced risk of serious ovarian cancer

New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serious ovarian cancer—an aggressive carcinoma affecting the surface of the ovary.

10 Oct 2012

Incidence of esophageal, stomach cancers increased in AIDS

The risk for esophageal and stomach carcinomas, as well as non-Hodgkin lymphomas, is significantly increased in people with AIDS, although the incidence of lymphomas has decreased, the results of a US and UK study reveal.

1 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Breath testing could discriminate between benign and malignant pulmonary nodules

A pilot study, published in the October 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed that breath testing could be used to discriminate between benign and malignant pulmonary nodules.

17 Sep 2012

Genomes of lung cancer smokers have more mutations

Lung cancer patients with a history of smoking have 10 times more genetic mutations in their tumors than those with the disease who have never smoked, according to a new study from Washington University School of Medicine in St. Louis.

14 Sep 2012

Optimal approach for esophageal cancer surgery varies

Accurate preoperative staging of junctional adenocarcinoma of the esophagus can impact the surgical approach used, and postoperative outcomes vary according to the patients’ stage of disease, report German researchers.

13 Sep 2012

Platinum tissue concentrations predict NSCLC treatment response

Reduced tissue platinum accumulation might explain why some patients with non-small-cell lung cancer fail to respond to platinum-based chemotherapy, research shows.

13 Sep 2012

Minimally invasive esophagectomy viable alternative to open surgery

Patients undergoing surgery for esophageal cancer may benefit from minimally invasive techniques as much as they do from open surgery, say researchers.

11 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

Researchers identify genetic variations linked with onset of Barrett's oesophagus

Genetic variations that are linked with the onset of Barrett's oesophagus (BE), a pre-cancerous condition of the lower end of the gullet, have been identified for the first time. The discovery of variations in regions on two chromosomes makes it possible to develop screening tests for people at high risk of developing the disease.

10 Sep 2012

More women and non-smokers being diagnosed with non-small cell lung cancer

There has been an increase in the number of non-smokers being diagnosed with non-small cell lung cancer, according to new findings.

5 Sep 2012

New research reveals why some lung cancers are undetected by radiograph

New research has revealed why some lung cancers are undetected by radiograph and helped to identify the type of people who may be at risk of this form of the disease.

3 Sep 2012

Anastomotic leakage does not increase rectal cancer recurrence risk

Incidence of clinical anastomotic leak after anterior resection for patients with rectal adenocarcinoma does not increase the risk for local disease recurrence, despite previous studies indicating the opposite, report US researchers.

30 Aug 2012

NIH awards $100,000 STTR Phase I Grant to Transgenomic for pancreatic cancer research

Transgenomic, Inc. today announced it has been awarded a $100,000 Small Business Technology Transfer Program (STTR) Phase I Grant by the National Institutes of Health's National Center For Advancing Translational Sciences.

23 Aug 2012

Heartburn and cancer: an interview with Mindy Mintz Mordecai

What most of us think of as heartburn is a symptom of Reflux Disease or GERD (Gastroesophageal Reflux Disease). It’s that burning discomfort an individual experiences when stomach acids and other fluids come back up into their esophagus.

14 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012